Recent Updates
Recently added Catalysts
INCY Positive Sentiment

Incyte to Report First Quarter 2026 Financial Results

Key Takeaway: Incyte has announced a conference call to discuss its first quarter financial results for 2026, scheduled for April 28 at 8:00 a.m. ET. The call will be accessible via a live webcast and will have a replay option available for thirty days. Incyte continues to highlight its focus on innovation in biopharmaceuticals.
Price reaction · baseline $96.96 (2026-04-09 close) · hit pre-market · clean, no other INCY news in the window
day 0 close · peak
-0.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Incyte is actively engaging with investors through scheduled calls.
  • The company showcases a strong commitment to transparency with replay options.
  • Incyte emphasizes its innovative approach in biopharmaceuticals.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+44%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
INCB013739
Phase 2 · Type 2 Diabetes

Full Press Release Details

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 28, 2026.
The schedule for the press release and conference call/webcast is as follows:
If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415.To access the replay you will need the conference ID number 13759527.
The live webcast with slides can be accessed atInvestor.Incyte.comand will be available for replay for ninety days.
About Incyte®
Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity.
To learn more, visitIncyte.comandInvestor.Incyte.com. Follow us on social media:LinkedIn,XandInstagram.

Frequently Asked Questions

When is Incyte's Q1 2026 financial results call?

The call is scheduled for April 28, 2026, at 8:00 a.m. ET.

How can I access the Incyte conference call?

You can access the call via a live webcast at Investor.Incyte.com.

Is there a replay available for the conference call?

Yes, a replay will be available for thirty days after the call.

What is Incyte's focus in biopharmaceuticals?

Incyte focuses on hematology, oncology, and inflammation and autoimmunity.

Last updated: Apr 10, 2026